Mandate

Vinge has advised the arranging banks in connection with Svenska Handelsbanken’s issue of Convertible Additional Tier 1 Capital in the amount of MUSD 500

February 19, 2019 Banking and Finance

Vinge has advised Morgan Stanley & Co. International plc and the other arranging banks consisting of Citigroup Global Markets Limited, Deutsche Bank AG, London Branch, Svenska Handelsbanken AB (publ) and UBS Limited in respect of Swedish law in connection with Svenska Handelsbanken’s issue of Additional Tier 1 bonds in the amount of approximately MUSD 500.

The bonds are perpetual instruments without a final maturity date, without the right of premature redemption during the first five years and with an automatic conversion to class A shares in the event that the bank’s core equity capital falls below a certain level. 

The issue will strengthen the bank’s core equity capital by 0.6 points. The issue will be subscribed and allocated to the arranging banks on 22 February 2019. 

The bonds will be listed on Euronext Dublin. 

Vinge’s team consisted of Mikael Ståhl, Josefine Larsson, Malte Hedlund and Paulina Malmberg.
 

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025